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Transplant-Associated Thrombotic
Microangiopathy in Pediatric
Hematopoietic Cell Transplant
Recipients: A Practical Approach to
Diagnosis and Management
Christopher C. Dvorak*, Christine Higham and Kristin A. Shimano
Division of Pediatric Allergy, Immunology, and Bone Marrow Transplant, Benioff Children’s Hospital, University of California,
San Francisco, San Francisco, CA, United States
Transplant-associated thrombotic microangiopathy (TA-TMA) is an endothelial damage
syndrome that is increasingly identified as a complication of both autologous and
allogeneic hematopoietic cell transplantation (HCT) in children. If not promptly diagnosed
and treated, TA-TMA can lead to significant morbidity (e.g., permanent renal injury) or
mortality. However, as the recognition of the early stages of TA-TMA may be difficult,
we propose a TA-TMA “triad” of hypertension, thrombocytopenia (or platelet transfusion
refractoriness), and elevated lactate dehydrogenase (LDH).While not diagnostic, this triad
should prompt further evaluation for TA-TMA. There is increased understanding of the
risk factors for the development of TA-TMA, including those which are inherent (e.g.,
race, genetics), transplant approach-related (e.g., second HCT, use of HLA-mismatched
donors), and related to post-transplant events (e.g., receipt of calcineurin inhibitors,
development of graft-vs. -host-disease, or certain infections). This understanding should
lead to enhanced screening for TA-TMA signs and symptoms in high-risk patients. The
pathophysiology of TA-TMA is complex, resulting from a cycle of activation of endothelial
cells to produce a pro-coagulant state, along with activation of antigen-presenting cells
and lymphocytes, as well as activation of the complement cascade and microthrombi
formation. This has led to the formulation of a “Three-Hit Hypothesis” in which
patients with either an underlying predisposition to complement activation or pre-existing
endothelial injury (Hit 1) undergo a toxic conditioning regimen causing endothelial injury
(Hit 2), and then additional insults are triggered by medications, alloreactivity, infections,
and/or antibodies (Hit 3). Understanding this cycle of injury permits the development of a
specific TA-TMA treatment algorithm designed to treat both the triggers and the drivers
of the endothelial injury. Finally, several intriguing approaches to TA-TMA prophylaxis
have been identified. Future work on the development of a single diagnostic test with
high specificity and sensitivity, and the development of a robust risk-scoring system, will
further improve the management of this serious post-transplant complication.
Keywords: thrombotic microangiopathy, atypical hemolytic uremic syndrome, hematopoietic cell transplantation,
endothelial injury, complement
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INTRODUCTION
Hematopoietic cell transplantation (HCT) for pediatric patients
has classically been limited by transplant-related mortality
(TRM). It has long been recognized that certain patients
undergoing HCT are at increased risk for the development
of endothelial injury, notably in the sinusoids of the liver,
which manifests as sinusoidal obstruction syndrome (SOS).
Recently, there has been an increased awareness that endothelial
injury outside of the liver sinusoids is also a common
occurrence in pediatric HCT recipients. This injury manifests
itself as a thrombotic microangiopathy (TMA), with the most
common features being hemolytic anemia, thrombocytopenia,
hypertension, and renal dysfunction.
As a robust single-diagnostic test does not yet exist, the
incidence of transplant-associated (TA)-TMA is poorly defined,
but likely ranges from 10 to 35% (1). This variability is in large
part due to the lack of standardly-applied consensus criteria
as well as the significant limitations of the criteria themselves.
Currently, the best criteria for pediatric patients are those
proposed by Jodele et al. (2), while in our experience other
criteria are less useful due to their reliance upon the presence
of schistocytes (3–5). Despite issues with non-standardized
definitions, one thing is certain: patients who develop TA-TMA
have significantly higher rates of TRM (2, 6, 7), making the
diagnosis and management of this disease of critical importance.
Globally, TA-TMA fits into the general classification of
atypical hemolytic uremic syndromes (aHUS), as complement
has shown to play a major role in the pathophysiology of
the disorder. While post-HCT thrombotic thrombocytopenic
purpura (TTP) has been reported (8), it is extremely uncommon
compared to TA-TMA. Nevertheless, a first step toward treating
a patient with suspected TA-TMA features is to rule out TTP by
documenting normal levels (>10%) of ADAMTS13 and normal
von Willebrand Factor (vWF) multimers, since treatment of
TTP differs significantly from TA-TMA. Similarly, because the
treatment is quite different from TA-TMA, ruling out classic
HUS due to Shiga toxin-producing E. coli (STEC) is warranted,
though it is also very rare to see that disease in post-HCT
patient. However, onset of TMA symptoms 5–10 days following
an episode of abdominal pain, vomiting, and diarrhea should
prompt consideration of a stool culture and testing for the Shiga
toxin. Finally, while a modified version of the Ham test has been
shown to distinguish aHUS of transplant from other TMAs (9),
in our experience this is generally not needed in clinical practice.
PATHOPHYSIOLOGY OF TA-TMA
The pathophysiology of the vascular endothelial injury found
in patients with TA-TMA is extremely complex, but can be
simplistically broken down into three major pathways:
1. Activation of endothelial cells to produce a pro-coagulant
state. When damaged by conditioning agents and
other medications, activated endothelial cells undergo
multiple changes:
a) Tissue Factor is expressed on the cell surface. This
binds Factor VIIa (FVIIa), which promotes thrombus
formation with activated platelets. Increased production
of plasminogen activator inhibitor-1 (PAI-1) prevents
fibrinolysis of the clot.
b) Decreased levels of NO and prostacyclin (PGI2) leads to
loss of suppression of the activation of the coagulation
cascade and complement. Hemolysis leads to production
of free hemoglobin, which further decreases NO levels.
c) Decreased VEGF levels, in combination with release
of ANG2 from endothelial cells and binding to the
Tie2 receptor leads to vascular destabilization and
vascular leakage.
d) Increased expression of adhesion molecules (E-selectin,
ICAM-1, VCAM-1) permits the local recruitment of
antigen presenting cells (APCs) and lymphocytes.
e) Damaged endothelial cells release IL-8.
f) Endothelial cells and cell-derived micro-particles are
formed and released into the blood (10, 11).
2. Activation of antigen-presenting cells (macrophages and
neutrophils) and lymphocytes. The activated endothelial cells
in turn cause activation of a number of immune effector
cells, including:
a) IL-8 activates neutrophils to release NETs (which activate
complement via complement factor P/properdin) (12).
b) APCs express TNF-alpha, IFN-gamma, IL-1, IL-6, IL-
8, and IL-12, further stimulating activation of T-cells
and monocytes/macrophages.
c) IFN-gamma and TNF-alpha enhance class II HLA-
antigen expression on endothelial cells, making themmore
susceptible to T-cell mediated alloreactivity.
d) Activated B-cells can potentially produce pathogenic
antibodies. These include recipient-specific antibodies
directed against class II HLAmolecules (which can activate
the classical complement cascade) (13), or anti-factor H
auto-antibody production (which then prevent inhibition
of the alternative complement pathway).
3. Activation of the complement cascade and microthrombi
formation. The immunologic response activates both the
alternative and classical complement cascades, as well as
precipitates the formation of micro-thrombi:
a) Activation of C3 by hydrolysis leads to formation of C3b
which covalently binds to an endothelial cell surface. C3b
binding is further propagated by endothelial injury.
b) Once C3b is bound to the cell surface, complement Factor
B (CFB) binds to C3b and is cleaved by complement factor
D (CFD) leading to further amplification of alternative
complement pathway, ultimately leading to C5 cleavage to
C5a and C5b and formation of the lytic membrane attack
complex (MAC, C5b-9) on the endothelial cell surface,
causing direct endothelial cell lysis.
c) C5a, a potent anaphylatoxin, releases the anticoagulant
molecule heparan sulfate from the surface of the
endothelial cells.
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d) Classical complement activation by antigen/antibody
complexes actives C1 to trigger conversion of C4 to C4d,
which remains covalently bound to tissues such as the
glomeruli and intestines (14, 15).
e) Tissue damage and inflammation leads to increased
endothelial permeability, red cell (RBC) and platelet
extravasation, fibrin deposition, and micro-thrombi
formation along microvascular wall resulting in affected
organ ischemia.
The end sum of these pathways is the death of endothelial cells
and micro-thrombi formation. An excellent illustration of the
pathophysiology of TA-TMA can be found in Jodele et al. (1).
CLINICAL AND LABORATORY FEATURES
OF TA-TMA
In pediatric patients, TA-TMA typically occurs early post-
allogeneic HCT, with a median diagnosis at 35–47 days post-
HCT, and 88–92% occurring before Day +100 (2, 16). However,
cases have been reported up to 2 years post-HCT (6, 17).
Autologous recipients may develop TA-TMA even earlier, with
a median of 18 days post-HCT (18). Not all features appear
simultaneously, and in retrospect, it is often easy to appreciate
that sub-clinical TA-TMA was developing for days, if not weeks,
prior to the official diagnosis. As detailed below and in Table 1,
prompt diagnosis of TA-TMA requires regular monitoring and
trending of certain lab tests, especially in high-risk patients.
Hypertension is often the first clinical sign of impending TA-
TMA, typically proceeding formal diagnosis by a week or more
(2, 19). Unfortunately, hypertension is very common post-HCT,
especially in patients receiving calcineurin inhibitors (CNI), such
as tacrolimus and cyclosporine. A rule of thumb in the pediatric
HCT recipient is to suspect TA-TMAwhenever a patient requires
one additional anti-hypertensive medications beyond what is
typical for the patient’s clinical situation (1). For example, it may
be normal for a patient on a CNI to require one anti-hypertensive,
but addition of a second agent should prompt an investigation
for TA-TMA. Similarly, unless they are admitted with a history
of hypertension, autologous recipients or patients receiving ex
vivo T-cell depleted HCTs should not require any routine anti-
hypertensive medications, and initiation of one should trigger
consideration of impending TA-TMA.
The other clinical features, including thrombocytopenia
[especially platelet transfusion refractoriness, as also seen in
SOS (20)], elevated lactate dehydrogenase (LDH), proteinuria,
anemia, and falling haptoglobin begin to appear shortly thereafter
(2). All institutions should strongly consider routine monitoring
of LDH twice weekly for the first 100 days post-HCT. In
patients with thrombocytopenia and anemia, a critical distinction
to make is hypoproduction (as part of the normal post-HCT
marrow recovery or from marrow suppressive medications)
vs. destruction (as in TA-TMA). A frequent interval between
transfusions can be a clue to destruction, as can testing for
elevations in the immature platelet fraction and the reticulocyte
count, though this can be low early post-HCT. As the typical
first three signs to manifest, hypertension, thrombocytopenia,
TABLE 1 | Clinical and laboratory features of TA-TMA: differential diagnosis and
evaluations.
Clinical sign (in
typical order of
presentation)
Clues/tips Differential
diagnoses
Useful
evaluations
THE TA-TMA “TRIAD” (PRESENT IN ALMOST ALL CASES)
Hypertension
(>95% for age, sex,
height)
Requiring >1 BP
Med (or >0 if not
on a CNI/
steroids)
CNI, Steroids
de novo
Thrombocytopenia/
platelet transfusion
refractoriness
No rise in platelet
count the day
after transfusion
SOS,
Anti-platelet
antibodies
Bilirubin, liver US
Post-transfusion
count
Immature
platelet fraction
Elevated LDH
(>ULN for age)
Need to monitor
twice weekly &
trend
Liver injury, AIHA Liver enzymes
Direct
antiglobulin test
OTHER FINDINGS
Proteinuria
(≥30 mg/dL)
Need to monitor
UA daily
Send Urine
Protein/Cr if
UA positive
Cystitis Urine and blood
PCR for BK virus
& adenovirus
Elevated D-dimers Need to monitor
twice weekly
and trend
Sepsis/DIC,
SOS
Blood cultures
Falling haptoglobin May rise first as
an inflammatory
acute phase
reactant, such
that the fall can
be late
AIHA Direct
antiglobulin test
New Anemia/
increased RBC
transfusion needs
AIHA Reticulocyte
count
Rising creatinine Late finding CNI, Other meds
(anti-virals), BK
nephritis
Blood PCR for
BK virus
Schistocytes Often absent Fairly
pathognomonic,
when present
Bold, Part of Current Diagnostic Criteria of Jodele et al. (2) along with sC5b9, though
not all required to be present in order to make the diagnosis. BP, blood pressure; CNI,
calcineurin inhibitor; SOS, sinusoidal obstruction syndrome; US, ultrasound; LDH, lactate
dehydrogenase; ULN, upper limit of normal; AIHA, autoimmune hemolytic anemia; UA,
urinalysis; DIC, disseminated intravascular coagulation; RBC, red blood cell.
and elevated LDH can be considered the “TA-TMA triad,” akin
to the SOS classic triad of hepatomegaly, weight gain, and
elevated bilirubin.
One of the diagnostic criteria suggests that patients with TA-
TMA should have normal coagulation studies (prothrombin time
and activated partial thromboplastin time) to exclude cases of
disseminated intravascular coagulation (DIC) (3). However, in
our experience this should not be considered a hard and fast rule,
since patients may have other reasons for abnormal coagulation
studies (such as prior or concomitant SOS). Furthermore, it is
typically easy clinically to distinguish patients with DIC (who are
usually tachycardic and hypotensive) from those with TA-TMA
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(who are invariably hypertensive). Fibrin D-dimers, a sign of
intravascular clot formation and breakdown, are not part of any
current criteria. However, in our experience they are extremely
sensitive (albeit non-specific) marker for active TA-TMA, such
that their absence should prompt consideration of alternative
causes for the patient’s clinical signs and symptoms. One report
suggested that D-dimers, in combination with other markers of
endothelial injury (angiopoietin-2 [ANG2], C-reactive protein
[CRP], and thrombomodulin [TM]), can help define TA-TMA as
well as the risk of subsequent TRM (21). Others have also noted
increased D-dimer levels in TA-TMA (22).
Although not part of the current criteria, in addition to
proteinuria, hemoglobinuria is also commonly present. Rising
creatinine can be a late feature of TA-TMA and is fairly
concerning that irreversible kidney injury has begun. Cystatin C
may be a better indicator of early renal dysfunction, but it is less
readily available (23). With the other diagnostic features present
and other diagnoses on the differential list excluded, we firmly
believe that clinicians should not wait for signs of renal injury in
order to diagnose TA-TMA. A significant percentage of patients
eventually go on to develop renal failure requiring the initiation
of dialysis (6).
The presence of schistocytes on a peripheral blood smear
should be the pathognomonic marker of TA-TMA, but because
this is a subjective test requiring interpretation from a skilled
microscopist, at many institutions it may be of very limited
utility and therefore should not be relied upon to verify the
diagnosis of TA-TMA (24). There is also the possibility that high
vascular permeability leads to extravasation of the fragmented
erythrocytes so that they are no longer in active circulation (19).
When all else fails, histologic evidence of microangiopathy
on biopsy of an affected organ (e.g., kidney or intestine) is the
gold standard to the diagnosis of TA-TMA. In our experience,
however, such invasive procedures are rarely required to confirm
the diagnosis and, in patients with severe thrombocytopenia
from TA-TMA, are associated with a significant risk of
serious bleeding.
While the hallmark of TA-TMA is kidney involvement,
it is important to recognize that other organs may also be
compromised in TA-TMA, especially the gastrointestinal tract
(manifested as abdominal pain, nausea, bleeding, and ileus)
(25), serosal surfaces (manifested as pericardial and pleural
effusions) (26, 27), the cardiopulmonary system (manifested as
pulmonary arterial hypertension) (28), and the neurologic system
(manifested as confusion, headaches, and seizures) (1).
INVESTIGATIONS AT FIRST CLINICAL
SUSPICION OF TA-TMA
1. Ruling Out Other Diagnoses on the Differential
a) Other TMAs: As noted above, documentation of a normal
ADAMTS13 level and negative stool Shiga toxin are
technically warranted.
b) Autoimmune hemolytic anemia (AIHA): Direct antibody
testing (Coombs) should be performed on all post-
HCT patients with anemia, elevated LDH, and low
haptoglobin. In rare cases, patients may have both
AIHA and immune thrombocytopenia (ITP) post-HCT,
but even this is typically distinguishable from TA-TMA
due to the lack of hypertension and proteinuria in the
former setting.
c) Liver SOS: TA-TMA shares certain features with SOS,
especially the platelet refractoriness and fluid retention.
However, coagulation studies (such as the INR and aPTT)
are typically normal in TA-TMA and elevated in SOS.
Bilirubin may not always be elevated in pediatric patients
with SOS, so a liver ultrasound with Doppler evaluation for
reversal of portal venous flow may be useful (20).
Overall, few diseases in HCT patients fully mimic the entire
picture of TA-TMA and therefore, in at-risk patients (see
below), the development of associated signs and symptoms
should be considered TA-TMA until proven otherwise.
In other words, when you hear the TA-TMA triad of
“hypertension, thrombocytopenia, and elevated LDH,” TA-
TMA should be considered a “horse,” not a “zebra.”
2. Evaluating the Extent and Risk of TA-TMA (Table 2)
a) Complement system: C3 levels may be low in patients
with TA-TMA, suggesting a state of complement activation
(29). Additionally, serum complement membrane attack
complex sC5b9 levels may be elevated due to terminal
complement activation. Although a supportive feature for
the diagnosis, not all patients with TA-TMA have an
elevated sC5b9 level. Patients with elevated sC5b9 levels,
TABLE 2 | Evaluations to perform after confirmation of TA-TMA.
Evaluation Notes
Complement: C3, sC5b-9, CH50 C3 level is typically low (representing
consumption)
Elevated sC5b9 is a risk-factor for poor
outcome
Baseline CH50 useful if eculizumab is to
be administered
Reticulocyte count (trend) and
Immature Platelet Fraction (trend)
Useful to determine if marrow production
is able to keep up with destruction
GVHD biomarkers:
ST2, REG3-alpha, ± HGF, ±
Elafin
Useful to determine if GVHD is driving the
TA-TMA
Chimerism (T-cell) May be useful to determine if sub-clinical
GVHD is driving the TA-TMA
CRP (trend) May be useful to determine if uncontrolled
inflammation is driving the TA-TMA
Viral PCRs (CMV, Adenovirus,
HHV-6, BK) and Galactomannan
Useful to determine if uncontrolled
infection is driving the TA-TMA
Antibodies to CFH & Class II HLA Marker of antibody-mediated TA-TMA
Electrocardiogram and
Echocardiogram
Request specific evaluation of RV pressure
and Tricuspid Regurgitation Velocity
Consider genetic panel
(complement)
Must be done on buccal swab or banked
DNA (if allogeneic HCT)
GVHD, graft-vs.-host disease; ST2, suppressor of tumorigenicity 2; REG3, regenerating
islet-derived 3; HGF, hepatocyte growth factor; CRP, C-reactive protein; CMV,
cytomegalovirus; HHV-6, human herpes virus-6; CFH, complement factor H; HLA, human
leukocyte antigen.
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however, are at increased risk of death from TA-TMA (2),
and so this test can serve as a marker for patients who
absolutely should be treated with complement blockade
(see below). When complement blockade is utilized as
treatment, CH50 levels are a marker of efficacy, and a
baseline CH50 therefore should be performed as part of
the workup.
b) Gastrointestinal tract: The gastrointestinal (GI) tract is
often involved with TA-TMA and can present with
symptoms which mimic GI GVHD, such as diarrhea,
vomiting, pain, and bleeding (25). If the patient does not
have evidence of GVHD elsewhere, an endoscopy with
biopsies may be required to distinguish incompletely-
treated TA-TMA vs. active GVHD, though the treatments
for these may overlap (see below).
c) Serosal surfaces: While classically thought of as a
manifestation of chronic graft- vs. -host disease (GVHD),
in our experience all patients with evidence of pleural
and pericardial effusions on chest radiograph and
echocardiogram should be evaluated for TA-TMA
(26). If clinically significant (i.e., respiratory distress or
tamponade), the fluid may require drainage. However,
because the fluid will continue to re-accumulate until
the pathophysiology behind the serositis resolves, a
one-time drainage procedure, such as pleurocentesis
or pericardiocentesis is typically insufficient. If an
intervention is to be performed, drains should typically
be left in place until there are signs that the serositis is
improving. For patients with pericardial effusions, in order
to minimize the infectious risk of a prolonged external
drain, a pericardial window may be necessary.
d) Cardio-pulmonary: Cardiac evaluation should be
performed on all patients with TA-TMA, as they are
at increased risk for pulmonary arterial hypertension
(PAH), which if not recognized and treated, may be
deadly (1, 28). Clinically, hypoxemia or respiratory
distress may be noted, but as these are late findings,
work-up should proceed even in asymptomatic patients
(1). An electrocardiogram may demonstrate right axis
deviation, while the echocardiogram needs to be requested
to specifically evaluate for evidence of right ventricular
(RV) dysfunction, such as a RV pressure >35% (50% in
adults) of systemic and a tricuspid regurgitation velocity
of >2.9 m/second (1). Any evidence of PAH should
prompt evaluation by an experienced PAH-team who can
assist with further work-up and management. One report
noted that an echocardiogram done on all patients at
Day +7 post-HCT may be an excellent tool for screening
which patients are about to develop clinically-apparent
TA-TMA (27).
e) Neurologic: Tight control of hypertension can
potentially mitigate neurologic complications, but
if such symptoms develop, a brain MRI should be
performed. It may demonstrate bilateral white matter
abnormalities in the vascular watershed areas consistent
with posterior reversible encephalopathy syndrome
(PRES) (30).
f) Immunologic evaluation: Evaluating and trending a
CRP can be a useful marker of excessive inflammation
(21). While most TA-TMA is mediated by complement,
rare patients can instead have a process driven by
autoantibodies, typically to Complement Factor H (CFH),
a negative regulator of the alternative pathway (31). It is
also thought that other recipient-specific autoantibodies
against class II HLA-molecules or other endothelial
proteins may be involved (13, 32). One potential clue
to this rare occurrence may be a sudden rise in
B cell numbers on lymphocyte phenotyping or other
autoimmune manifestations. An ELISA test for anti-CFH
antibodies is also clinically available.
g) Genetics: Primary atypical HUS occurring outside of
the setting of HCT is typically mediated by gain-of-
function mutations in genes encoding complement or
by deficiencies in genes responsible for complement
regulatory proteins (33). These pathologic mutations drive
microangiopathy without significant stressors, but are
very rare (<five per million). Conversely, 65% of TA-
TMA patients will have one or more “benign” variants in
complement genes detected. Although not urgent, testing
for mutations in complement genes may be useful when
determining length of complement blockade therapy, if
used (see below). Commercial tests for mutations in
CFH, MCP (CD46), CFI, C3, CFB, CFHR1, CFHR3,
CFHR4, CFHR5, TM, Plasminogen, and DGKE are all
available. Obviously, because these are host proteins, in
the allogeneic setting this test must be done with DNA
obtained from a buccal swab or pre-HCT banked DNA.
RISK FACTORS
Especially in the allogeneic setting, numerous risk factors
have been identified. These can be separated into those that
are: (1) inherent and non-modifiable; (2) transplant approach-
associated; and (3) post-transplant event related (Table 3).
1. Inherent/Non-Modifiable Risk Factors
Genetics may play an important role in determining who
eventually develops TMA following an HCT. Variants in
complement genes are commonly found in all races, but
when multiple variants are found in an individual, the risk
of subsequent TA-TMA is significantly elevated (34). African-
American patients have been reported to have higher rates of TA-
TMA, perhaps because of an increased likelihood of possessing
more than one of the aforementioned activating variants in
complement genes due to a protective effect against Neisseria
infections (34). These “benign” gene variants are considered
insufficient to trigger aHUS in the absence of a serious endothelial
stressor; however, they become clinically apparent in the post-
transplant period. As most complement is produced in the liver,
these gene variants are typically host in nature, although one
report suggested that donor mutations may also be responsible,
since some complement appears to be made in monocytes and
platelets (35).
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TABLE 3 | Potential risk factors for TA-TMA.
Inherent/
non-modifiable
Transplant-associated Post-transplant events
Female sex HLA-mismatched donor CNI ± Sirolimus
Gene variants Minor ABO mismatch Infection
(Bacteremia or IFI)
African-American
race
Use of PBSC Infection
(DS-DNA Virus,
e.g., CMV, HHV-6, BK)
Severe aplastic
anemia
Lack of ATG in conditioning
regimen
Acute GVHD
CMV seropositive
recipient
Myeloablative conditioning Autoantibody formation
(Factor H, others)
Prior HCT Slow metabolism of
conditioning agents?
HLA, human leukocyte antigen; CNI, calcineurin inhibitor; ABO, blood type antigens;
IFI, invasive fungal infection; PBSC, peripheral blood stem cells; GVHD, graft-vs. -host
disease; CMV, cytomegalovirus; HHV-6, human herpes virus-6; ATG, anti-thymocyte
globulin; HCT, hematopoietic cell transplant.
Another report suggested that variants in CD40L, a gene
responsible for production of a protein which plays a central
role in co-stimulation and regulation of the immune response
via T cell priming and activation of CD40-expressing immune
cells, may increase the risk of TA-TMA (36). Finally, one report
suggested that carriers of HLA-DRB11 are at increased risk of
developing TA-TMA (37).
Surprisingly, females have been noted to have an increased
incidence compared tomales in several reports (6, 16, 38), though
the pathophysiologic basis for this finding is poorly understood.
One study of adults also noted an increased risk of TMA in CMV
seropositive recipients (39).
Having severe aplastic anemia (SAA) as an underlying
primary disease has been linked to increased rates of TA-TMA
(2). One hypothesis is that this is related to prolonged exposure
to CNIs pre-transplant. If so, differential rates should be seen in
those patients with SAA who proceed straight to HCT vs. those
who undergo immunosuppressive treatment first, but to date this
analysis has not been performed. Patients with chronic hemolytic
conditions such as sickle cell disease or beta-thalassemia may
also be at elevated risk, though the data for this is currently
limited (30).
2. Transplant Approach-Associated Risk Factors
In allogeneic HCT recipients, a prior transplant is reported
to increase the risk of TA-TMA (40). Similarly, in the
autologous setting, tandem myeloablative HCT for patients
with neuroblastoma (utilizing first cyclophosphamide and
thiotepa, followed 6–10 weeks later with carboplatin, etoposide,
melphalan) has been linked to high rates of TA-TMA (18).
The use of HLA-mismatched donors has been routinely
associated with higher rates of TA-TMA (6, 16, 37, 40, 41), as
has the use of peripheral blood stem cells (34). Blood group
A and B antigens are expressed on endothelial cells and may
serve as targets of attack in the setting of HCT from minor
ABO-mismatched donors. Many reports suggest that minor ABO
mismatch is a risk factor for TRM (32, 42), and this may at least
partially driven by increased TA-TMA (40, 43, 44). The use of
ABO-incompatible platelets was noted to be a risk factor for the
development of SOS (45) though to date this question has not
been carefully studied in TMA.
The use of myeloablative conditioning is usually associated
with higher rates of TA-TMA compared to reduced intensity
conditioning (RIC) regimens (40, 41, 46), however, which specific
components of conditioning are most responsible remain to
be worked out. Total body irradiation (TBI) has been linked
to development of TA-TMA (16, 47), especially in patients
with low body mass index (48). Once administered, fludarabine
undergoes rapid dephosphorylation in the plasma to F-ara-A
(9-beta-D- rabinofuranosyl-2-fluoroadenine). This molecule has
been associated with endothelial injury and TA-TMA (49, 50).
In adults undergoing non-myeloablative HCT, 16% of patients
had high F-ara-A levels, which correlated with increased risk of
transplant-related mortality (51). A pediatric analysis of F-ara-A
levels did not show a correlation with TRM, though the rate of
TRM in the studied patients was low, limiting power (52). The
lack of anti-thymocyte globulin in the conditioning regimen is
also associated with higher rates of TA-TMA. This is likely due
to higher rates of GVHD in patients who do not receive ATG, as
development of GVHD is linked to TA-TMA (discussed below).
In patients with neuroblastoma, early recovery of ANC is
associated with increased risk of SOS (53). Although there is
no data to suggest that the use of G-CSF to hasten neutrophil
recovery post-HCT increases the risk of TA-TMA, given the role
of NETs (discussed below) in exacerbating the endothelial injury,
further investigation of whether there is a link between G-CSF
and TA-TMA is warranted.
3. Post-Transplant Event Risk Factors
The use of certain medications post-HCT has been associated
with increased risk of developing TA-TMA. The best-appreciated
agents are the CNIs, cyclosporine and tacrolimus, especially when
given in combination with sirolimus (37, 40, 41, 46, 54). The
mechanism appears to be at least due to decreased levels of nitric
oxide (NO) and vascular endothelial growth factor (VEGF). In
vitro there is evidence that cyclosporine alone is worse than
tacrolimus alone and similar to tacrolimus plus sirolimus (55),
though a major difference has not been demonstrated clinically.
It is now well appreciated that acute GVHD is tightly
linked to the development of TA-TMA (7, 16, 37, 40, 41,
46, 56). Elevations in ST2, a marker of endothelial injury,
have been reported in corticosteroid-resistant GVHD (57),
and this finding may link TA-TMA as a form of endothelial
GVHD (58–61).
The development of certain infections post-HCT have been
associated with increased TA-TMA. Although TMA itself and its
treatment likely predisposes to the development of bacteremia,
this pathway is bidirectional, for multiple episodes of bacteremia
are strongly linked to subsequent development of TA-TMA (62).
This is likely mediated by the release of neutrophil extracellular
traps (NETs) into the vasculature (12, 63). NETs cause platelet
aggregation, thrombin activation, and fibrin clot formation (64).
Building upon these observations, since administration of G-
CSF to healthy volunteers increases NET levels (65), one possible
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hypothesis is that G-CSF use in HCT recipients may predispose
to or perpetuate TA-TMA, though to date there are no data
analyzing this potential risk factor. Fungal infections, especially
aspergillus, have been linked to TA-TMA (6, 16), possibly
mediated via the same pathway by which the angioinvasion
process leads to endothelial activation.
Double-stranded (DS) DNA viral infections such as CMV
and HHV-6, especially when occurring together, have been liked
to TA-TMA (16, 37, 56, 66). This process may be mediated
via production of cytokines such as TNF-alpha and IL-1. High
levels of BK viremia have also been linked to TA-TMA (67). The
role of DS-DNA viral infection in propagating TA-TMA may
explain why the use of alemtuzumab has not been associated
with decreased risk (unlike has been seen with ATG), given the
increased rates of infections noted with this agent (68).
Therefore, risk-assessment for TA-TMA has to occur at two
time-points, pre-HCT based on intrinsic and transplant-related
factors, but also post-HCT in the setting of new triggers such
as GVHD or infections. Higher-risk patients would likely benefit
from enhanced monitoring and clinicians having a higher index
of suspicion for the diagnosis of TMA.
An analysis of the aforementioned risk factors for the
development of TA-TMA lends support to a “Three-Hit
Hypothesis” (Figure 1) (69). First, patients with either an
underlying predisposition to complement activation (e.g., racial
or genetic) or a pre-existing endothelial injury (e.g., prior
myeloablative HCT or prolonged CNI use in SAA) (Hit 1),
further endothelial injury is mediated by the delivery of a
toxic conditioning regimen (Hit 2). Then, a third hit occurs
which perpetuates continued endothelial injury and represents
a threshold level for triggering activation of the complement
system. This can be caused by medication toxicity (CNI,
sirolimus), alloreactivity (GVHD), infectious (bacterial or viral),
antibody-mediated, or some combination of all of these (Hit 3).
As we learn more about the risk-factors for the development
TA-TMA, this hypothesis may require further modification.
TREATMENT OF TA-TMA
Although definitive proof is lacking, by analogy to SOS, another
endothelial damage syndrome, early therapy is predicted to result
in improved survival and long-term outcomes, therefore close
monitoring of at-risk patients is potentially very important. One
simple measure to suggest patients at high-risk for doing poorly
is the “TMA Index,” calculated by dividing the LDH (in IU/L) by
the platelet count (in X109/L) (16). Patients with a score of <20
typically do well, while those with a score of >100 have very poor
outcomes. Proteinuria and an elevated sC5b9 level are also poor
prognostic markers.
Adjunctive Treatment
1) Anti-hypertensives: All patients with TA-TMA have
hypertension and require multiple anti-hypertensives.
However, not all agents may be equally beneficial. Because
of the involvement of the renin-angiotensin system in
mediating hypertension in TA_TMA, blocking this system
with ACE-inhibitors or angiotensin 2 receptor agonists may
be preferred (1, 70). However, in patients with significant
kidney injury, calcium channel blockers may initially be safer
due to their vasodilatory properties.
2) Erythropoietin and Thrombopoietin: Both PRBCs and
platelet units contain plasma with significant amounts of
complement (71, 72). Therefore, transfusions in patients
undergoing complement blockade may be counter-
productive and should be limited as much as possible
(1), and volume-reduced platelets may be considered
when transfusions are required. Patients with significant
renal injury from TA-TMA may be erythropoietin
(EPO) deficient, and careful administration of exogenous
EPO to support reticulocytosis should be considered
(73). Similarly, if immature platelet fractions are low,
careful use of thrombopoietin receptor agonists, such
as oral eltrombopag or subcutaneous romiplostim, may
be considered, though there are currently no data in
TA-TMA patients.
Specific Treatment Algorithm
Various therapies have been considered for TA-TMA, but
overall survival rates remain worse than for the general
population of post-HCT patients without TA-TMA (39, 41).
An algorithm for the approach to treatment is proposed
in Figure 2. Once a patient meets criteria for TA-TMA, it
asks a series of questions to help guide the clinician to
the treatment path most likely to improve the symptoms of
TA-TMA and thereby optimize survival and long-term renal
function. This algorithm contains several recommendations
which are variably supported by studies (as noted), as well as
anecdotal experience, and can be adapted to match an individual
institution’s unique situation. The first five questions relate to
recognizing and treating the various triggers of TA-TMA, as it
is unlikely to resolve until these triggers have also been brought
under control.
Question 1: Is the patient actively infected?
Certain infections appear to contribute to the endothelial
injury of TA-TMA. Anecdotally, this can include low-level
viremia from DS-DNA viral infections. All efforts to suppress
such viruses to the level of PCR-negativity should be employed,
including modulation of immunosuppression, anti-viral agents,
and potentially virus-specific cytotoxic T-cells (VS-CTLs). One
report demonstrated that TA-TMA will not resolve if the
underlying infection is not controlled (6). Unfortunately,
many currently available anti-viral agents can further induce
renal injury, and the potential benefit of modulation of
immunosuppression and VS-CTLs needs to be carefully weighed
against the risk of triggering alloreactivity.
Question 2: Does the patient have active GVHD?
There is clear evidence that active GVHD propagates
the endothelial injury of TA-TMA. All efforts to minimize
alloreactivity should be employed. The mainstay of this would
be treatment with corticosteroids, though for patients without
full response, consideration of other immunosuppressive agents
should be considered, especially those which might target
cytokine pathways also implicated in the TA-TMA pathway,
such as TNF-a and IL-1 (22, 74, 75). One report demonstrated
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FIGURE 1 | The “Three-Hit” hypothesis for the development of TA-TMA.
FIGURE 2 | TA-TMA treatment algorithm.
that TA-TMA will not resolve if the triggering GVHD is not
controlled (6).
Question 3: Could the patient have sub-clinical GVHD (or
excessive inflammation)?
Despite a lack of clinical GVHD, a patient may still
have sub-clinical alloreactivity driving endothelial injury. We
have anecdotally observed improved response to eculizumab
in autologous recipients as compared to those undergoing
allogeneic HCT, suggesting that unappreciated GVHD-mediated
endothelial injury may exist in some patients. This can be
difficult to document, but measurement of the CRP may provide
information about the global state of inflammation. Another
clue might be the state of donor T-cell chimerism. It has been
shown that mixed T-cell chimerism implies a state of tolerance
between donor and host, while full donor T-cell chimerism
suggests that tolerance has been broken and the patient is at
risk for (potentially sub-clinical) GVHD (76, 77). In this setting,
or in autologous patients, careful use of corticosteroids may be
considered in patients with other signs of excessive inflammation,
such as engraftment syndrome.
Question 4: Is the patient on a CNI (or sirolimus)?
For patients who develop signs of TA-TMA while receiving
CNIs for prophylaxis or treatment of GVHD, the first
intervention is typically to rapidly discontinue the CNI (16).
Depending on the clinical context, the patient may require
the initiation of an alternative anti-GVHD agent. Typically,
corticosteroids or mycophenolate mofetil is employed in these
situations. Another class of agents used in this situation are IL-
2 blockers (78), with basiliximab the currently available agent.
Sirolimus is likely a poor option in this setting due to its
association with TA-TMA when combined with tacrolimus.
Discontinuing or changing the GVHD drug does not always
reliably resolve TA-TMA; however, if caught early, this strategy
may be sufficient for some patients (6, 7).
Question 5: Could the patient have an autoantibody?
One hallmark feature of TA-TMA, unlike TTP, is a general lack
of response to therapeutic plasma exchange (TPE) (19, 44, 79, 80).
This is likely because most patients do not have an autoantibody
driving the pathophysiology of their TMA. However, in the
subset of patients with an autoantibody against Factor H or other
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endothelial proteins, the best therapy may indeed be antibody
removal via TPE, in combination with blockade of further
production via administration of rituximab, given immediately
after a TPE session (1, 31, 81).
TPE is invasive, as it often requires placement of a dedicated
pheresis line, placement of which can be risky in a severely
thrombocytopenic patient. If initiated, TPE should be performed
daily at first (80). Other potential benefits of early initiation
of TPE include: replacing dysfunctional complement regulators,
removing in?ammatory cytokines, and removing promoters of
endothelial damage, such as Ang-2, circulating endothelial cells,
endothelial micro-particles, and circulating free hemoglobin
(which binds to NO) released from damaged RBCs (10, 19, 82).
We have anecdotally noted that LDH levels decrease in response
to TPE faster than other hematologic parameters respond, which
may be simply a matter of clearance but not actual disease
resolution, so this lab marker alone should not be used to guide
treatment course.
If a patient responds to TPE, it should be continued daily until
complete resolution of the abnormal hematologic markers. TPE
is then weaned to every other day for a period of about 2 weeks,
then to twice weekly, and finally discontinued (80).
Question 6: Does the patient have proteinuria and/or an
elevated sC5b9 level?
In pediatric patients, the best prognostic criteria identified to
date has been the presence of proteinuria or an elevated sC5b9
(MAC complex) level (2). Patients with either abnormality should
be strongly considered for treatment with terminal complement
blockade, while patients with both should absolutely be started
on treatment. Eculizumab is a monoclonal antibody against C5
that prevents formation of the MAC. In patients with elevated
sC5B9 levels, use of eculizumab is associated with significantly
improved overall survival compared to untreated controls (56 vs.
9%; p = 0.003) (79). Another report confirmed excellent initial
responses to eculizumab, but cautioned that long-term overall
survival remained poor in patients with TA-TMA (83).
While eculizumab levels can potentially be performed and
correlate with response, practically, a fully suppressed CH50
is sufficient to demonstrate complete complement blockade
(79). The optimal dosing to achieve this may be different
than the package insert, as it has been demonstrated that
twice-weekly doses are often initially needed (79). Eculizumab
administration should not be combined with TPE, since the
TPE clears the antibody itself and continually replenishes C5,
thereby abrogating its effect. Furthermore, eculizumab may
block function of rituximab, as the latter depends on the
presence of complement (79). Therefore, the strategies of TPE ±
rituximab and complement blockade are generally considered to
be mutually exclusive (1).
In the US, eculizumab is only available through a Risk
Evaluation and Mitigation Strategy (REMS). This entails
counseling patients regarding the protective role of terminal
complement from the development of meningococcal infections
and providing them with a Patient Safety Card. Technically,
patients are supposed to undergo meningococcal vaccination 2
weeks prior to initiation of eculizumab. However, this is not
practical in the setting of TA-TMA, as patients may drastically
worsen during those 2 weeks, but more importantly, early post-
HCT, few patients will mount protective antibody titers to
vaccines, so this could inadvertently leave patients open to risk.
The standard practice in this setting is to provide antibacterial
prophylaxis with agents such as penicillin or ciprofloxacin until
eculizumab has been discontinued and CH50 levels return to
normal (84).
For patients who do respond to eculizumab, a common
dilemma is how long to continue the agent. If a pathogenic
mutation in a complement gene is located (i.e., Primary
aHUS), the answer is “lifelong.” However, most patients
who develop TA-TMA do not have a significant mutation,
but rather one or more minor gene variants. For these
patients, withdrawal of complement blockade can typically be
accomplished once all hematologic manifestations of the disease
(e.g., thrombocytopenia, anemia, elevated LDH, elevated D-
dimers, low haptoglobin) have resolved (1, 79). The median
number of doses to accomplish this is 10, but with a wide range of
4–52 (85). Renal manifestations of the disease (e.g., hypertension,
creatinine elevation, proteinuria) are less useful as markers of
when to discontinue therapy, as they may remain permanently
abnormal in the setting of significant renal injury (39).
Trials are currently underway to evaluate the use of
ravulizumab-cwvz (formerly ALXN1210), a long-acting
complement inhibitor, in pediatric patients with atypical HUS.
The data for this agent are currently limited to patients with
PNH, so its use in TA-TMA patients should be applied with
caution (86).
The typical TA-TMA patient who discontinues complement
blockade will not have recurrence of symptoms (79, 85).
However, if patients continue to have potential triggers of
endothelial injury or complement activation, then complement-
blockade should generally be continued until that trigger is no
longer present. For example, a patient with neuroblastoma who
develops TA-TMA after a tandemHCT will then typically receive
irradiation to their original tumor bed, an area that for most
patients includes a portion of the kidney. It is unclear whether
post-HCT immunotherapy with dinutuximab and IL-2 or GM-
CSF is a sufficient trigger, but small numbers of patients have
successfully gone through this treatment without eculizumab on
board (18).
Questions 4–6A: Is the patient responding to the intervention?
As noted above, most patients with TA-TMA will not
respond to plasmapheresis. One of the critical questions facing
a physician caring for a patient with TA-TMA, however, is how
long to wait for signs of response to an intervention before
deciding it is a treatment failure. As a general rule of thumb,
it takes at least 2–3 weeks to observe hematologic responses to
therapy (1, 6, 80).
While complement blockade has significantly improved
outcomes for patients with TA-TMA, a significant number (30–
40%) of patients do not respond (79, 85). For patients who are
not responding to complement-blockade, careful attention must
be paid to other factors which might be perpetuating endothelial
injury, with the recursive application of the questions in the
algorithm in Figure 2. If all of these options have been exhausted,
then alternative therapies must be considered.
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Alternative Therapies
a) Other Complement Blockers: Eculizumab works by blocking
the cleavage of C5 into C5a and C5b. However, C3b continues
to build up on RBCs, which then can be cleared in the spleen,
so extravascular hemolysis may continue (87). Furthermore,
some C5 variants prevent eculizumab binding. Therefore, for
patients with complement-driven disease, other complement
inhibitors are being actively evaluated in trials, including
coversin, a recombinant C5 inhibitor (88), and OMS721, a
human monoclonal antibody that inhibits mannan-binding
lectin-associated serine protease-2 (MASP-2).
b) Soluble Thrombomodulin: TM is a glycoprotein on the
surface of endothelial cells that, in addition to binding
thrombin, regulates C3b inactivation by factor I. Antibodies
against it have been linked to the development of aHUS. A
small case series in Japan demonstrated a beneficial role for
administration of recombinant TM to patients with TA-TMA
(89). Unfortunately, this product is currently unavailable in
the United States.
c) Defibrotide: Defibrotide is a mixture of single-stranded
oligonucleotides with endothelial protection properties
mediated via inhibition of TNF-alpha and via its pro-
fibrinolytic, anti-thrombotic, anti-inflammatory, and
thrombolytic properties. It is FDA-approved for the
treatment of SOS, another endothelial damage complication
of HCT, and it was therefore hypothesized that it would
play a role in the treatment of TA-TMA. Several reports
suggest a possible benefit (16, 81, 90, 91). The biggest concern
with using defibrotide in a patient with TA-TMA, who is
typically profoundly thrombocytopenic, is bleeding, though
the randomized trial in SOS prevention did not demonstrate
a difference in bleeding events between the intervention
and control arms (92). When used for management of SOS,
standard practice is to keep the platelet count above 30 ×
109/L. This may be challenging, however, given the general
desire to limit platelet transfusions (as noted above).
POTENTIAL APPROACHES TO
TA-TMA PROPHYLAXIS
None of the currently available treatments of TA-TMA have
resulted in 100% response rates. With the hypothesis that it is
easier to prevent a disease than treat it once fully established,
there have been many efforts to identify a safe and effective
prophylaxis regimen. While some of the TA-TMA risk factors
are not easily changed, others may be amenable to modification.
These approaches can be divided into those that improve baseline
endothelial health, those that decrease the initial endothelial
injury, and those that limit the “Third Hit.”
1. Improving baseline endothelial health
a. Vitamin D: In pediatric HCT patients, low baseline
Vitamin D levels have been associated with worse
overall survival (93, 94). In vitro, it has been
demonstrated that Vitamin D supplementation can
protect endothelial cells from radiation-induced damage
(95). Although not yet studied, it is possible that a trial
of Vitamin D normalization pre-HCT would partially
abrogate TA-TMA.
b. Eicosapentaenoic acid (EPA): EPA, one of the active
ingredients in fish oil, has been shown in one small trial to
decrease TA-TMA, potentially via reduction of cytokines
and stimulation of NO production (96). Larger trials
are warranted.
2. Limiting/repairing endothelial injury from conditioning
a. Individualized-Dosing: As the initial injury to the
endothelial cells is thought to be mediated by the damage
caused by the conditioning regimen, we hypothesize
that individualized dosing of these agents to account for
patient-specific differences in metabolism could limit
TA-TMA. An analogous prototype is busulfan, where
high exposures are associated with development of
SOS, GVHD, and TRM (97). PK-directed individualized
dosing of cyclophosphamide and fludarabine already exist
(52, 98), and studies are ongoing for melphalan, thiotepa,
and clofarabine.
b. Allopurinol: Uric acid is a product of dying cells, and levels
may become elevated following conditioning, especially in
patients with high disease burdens coming into transplant.
Elevations in uric acid have been shown to mediate
endothelial injury, possibly via NET formation (99). A
standard approach at some centers is to administer
allopurinol through conditioning, and a small trial of
rasburicase demonstrated lower rates of GVHD (100),
though a formal trial of allopurinol to prevent TA-TMAhas
not been performed.
c. Defibrotide: As noted above, defibrotide may play a role
in the treatment of TA-TMA. Defibrotide started the
day prior to conditioning has been demonstrated to
effectively provide prophylaxis against the development
of SOS in high-risk patients (92). In vitro, defibrotide
protects against endothelial injury induced by fludarabine
and CNIs (50, 55). A trial of defibrotide prophylaxis
in patients high-risk for development of TA-TMA is
underway (NCT#03384693).
d. Statins: Statins have a potential preventative role in TA-
TMA, as they have been shown to enhance endothelial cell
function inHCT patients (101). One retrospective report in
adults demonstrated significantly lower rates of TA-TMA
when patients were given pravastatin (20 mg/day) starting
on Day−1 (38). A pediatric trial has not been performed.
e. N-acetyl-L-cysteine (NAC): NAC is a synthetic anti-
oxidant derived from cysteine that acts by removing
reactive oxygen species (ROS) and regulating several
functions of the immune system. NAC can act directly, by
neutralizing ROS, or indirectly, by increasing glutathione
biosynthesis. In a mouse model of shiga-toxin mediated
aHUS, NAC significantly limited the endothelial injury
mediated via ROS (102). A small case series suggested a
benefit in patients with classic TTP via reduction of ultra-
large VWF multimers (103), but data are currently limited
in patients with TA-TMA.
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3. Limiting the “Third-Hit”
a. CNI-free GVHD prophylaxis: Since CNIs are commonly
implicated in the pathophysiology of TA-TMA, one
hypothesis is that their elimination from GVHD
prophylactic regimens should decrease the incidence
of TA-TMA. Thus far, studies of ex vivo or in vivo
T cell depletion in the matched donor setting have
not reported on TA-TMA rates (104), though renal
function at 1 year post-HCT seems improved (105).
However, TA-TMA has been observed in both autologous
transplants and ex vivo T-cell depleted haploidentical
HCTs, highlighting that CNIs are not the sole trigger of
endothelial injury.
b. Improved GVHD prophylaxis regimens: Since the
endothelium appears to be a target of GVHD, optimized
prophylaxis regimens that inhibit GVHD without
increasing infections would theoretically significantly
decrease rates of TA-TMA. Currently, the most promising
agent in this regard is abatacept (106), though data on
rates of TA-TMA after abatacept-containing regimens are
still lacking.
c. Improved Antimicrobial Prophylaxis: Because both
bacterial infections and DS-DNA viral infections are
possible mediators of the “Third Hit” of post-HCT
endothelial injury, interventions designed to minimize
them may have a secondary effect of also lowering the
incidence of TA-TMA. Levofloxacin has recently been
shown to decrease bacteremia in pediatric HCT recipients
(107). New anti-viral agents, such as letermovir and
brincidofovir, may also help minimize reactivations
that drive endothelial injury, though data on TA-TMA
rates in patients receiving newer prophylactic agents are
currently lacking.
d. Prophylactic Rituximab: As various endothelial-directed
antibodies may play a role in triggering TA-TMA,
prophylactic rituximab administration may abrogate this
risk. Rituximab has been used in the peri-transplant period
to prevent relapse, EBV reactivation, and GVHD, especially
in ex vivo T-cell depleted HCTs (108, 109), but data on
TA-TMA rates are currently lacking.
FUTURE DIRECTIONS
The field of TA-TMA would benefit from several critical
advances, including:
1) Development of a single diagnostic test with high sensitivity,
high specificity, and fast-turn around. One of the major
current limitations to rapid diagnosis (and hence treatment) is
the current reliance on a complex algorithm devised of clinical
and laboratory findings which may not all appear at the same
time. Several potential tests have been proposed, including:
a. MAC complex: Soluble C5b9 levels at Day 28 have been
tightly linked to later development of TA-TMA (110),
however, given that elevated levels are also associated with
poor outcomes, an earlier marker is probably required.
b. PAI-1: High levels of PAI-I have been associated
with development of TA-TMA (22, 111). However,
the utility of PAI-1 as a screening or diagnostic
test has not been rigorously evaluated in a large,
multi-center fashion.
c. Thrombomodulin: High levels at Day 14 post-HCT have
been significantly linked to subsequent development of
TA-TMA (111), and more recently, a panel of TM plus
D-Dimers, ANG2 and CRP has been proposed (21).
Unfortunately, a CLIA-approved test for TM does not yet
exist in the US.
d. Calpain: Calpain is a calcium-dependent, non-lysosomal
cysteine protease that functions as a platelet-aggregating
factor. A small study showed a correlation with the
presence and severity of TA-TMA, as well neurologic
symptoms (112). Unfortunately, a CLIA-approved test for
calpain does not yet exist in the US.
e. Haptoglobin degradation product: A novel biomarker of
haptoglobin fragments (consumed during the hemolysis
of TA-TMA) was recently identified, though it is still only
available as a research test at this time (113).
2) Establishment of a robust risk-scoring system. Although a
number of risk-factors for the development of TA-TMA have
been identified, their relative (and potentially additive) roles
have yet to be conclusively determined to enable robust
delineation of patients at very low and very high risk for TA-
TMA. Identification of a high-risk group would potentially
enable enhanced screening, and if a safe, effective, and
(ideally) inexpensive prophylactic agent were identified, this
would facilitate trials in those highest-risk patients.
3) Further consideration of routine up-front genetic testing.
Theoretically, HCT patients with a priori known variants
in complement genes might be candidates for a trial of
prophylactic complement blockade during the immediate
post-HCT period when endothelial damage is at its peak.
4) Formal evaluation of the prophylactic strategies noted above
with the best risk-to-benefit profile. The short list for such
trials would include vitamin D, EPA, allopurinol, statins,
and defibrotide.
CONCLUSIONS
TA-TMA is the end result of a complex pathophysiologic injury
to the endothelium in pre-disposed patients mediated by a
combination of conditioning-induced injury and a “Second
Hit” from medications (such as CNIs), GVHD, infections, or
antibodies. In recent years, there has been an increased awareness
of the risk of developing TA-TMA in pediatric HCT recipients.
However, given the current diagnostic limitations, a high index
of suspicion must be maintained, especially in high-risk patients
during the highest-risk time period post-HCT (∼21–100 days).
This is similar to the careful attention that pediatric transplant
physicians have historically paid to the development of SOS
and acute GVHD, both of which may overlap with TA-TMA.
The clinical TA-TMA triad of “hypertension (requiring one
more antihypertensive than expected for the clinical situation),
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thrombocytopenia (esp. platelet transfusion refractoriness), and
elevated LDH” should be constantly kept in mind. All institutions
should strongly consider routinely monitoring LDH twice
weekly for the first 100 days post-HCT, at least in high-
risk patients. Once TA-TMA is diagnosed, a simple treatment
algorithm can help guide the combination of interventions
required to halt further progression of endothelial injury and
allow the healing process to commence. In the future, one or
more agents may potentially help improve baseline endothelial
health and limit endothelial injury from both conditioning and
the “Second Hit.”
AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct and intellectual
contribution to the work, and approved it for publication.
REFERENCES
1. Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM, et al. A
new paradigm: diagnosis and management of HSCT-associated thrombotic
microangiopathy as multi-system endothelial injury. Blood Rev. (2015)
29:191–204. doi: 10.1016/j.blre.2014.11.001
2. Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, et al. Diagnostic
and risk criteria for HSCT-associated thrombotic microangiopathy:
a study in children and young adults. Blood. (2014) 124:645–53.
doi: 10.1182/blood-2014-03-564997
3. Cho B-S, Yahng S-A, Lee S-E, Eom K-S, Kim Y-J, KimH-J, et al. Validation of
recently proposed consensus criteria for thrombotic microangiopathy after
allogeneic hematopoietic stem-cell transplantation. Transplantation. (2010)
90:918–26. doi: 10.1097/TP.0b013e3181f24e8d
4. Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, et al.
Blood and marrow transplant clinical trials Network Toxicity Committee
consensus summary: thrombotic microangiopathy after hematopoietic stem
cell transplantation. Biol Blood Marrow Transplant. (2005) 11:571–5.
doi: 10.1016/j.bbmt.2005.06.001
5. Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A,
et al. Diagnostic criteria for hematopoietic stem cell transplant-associated
microangiopathy: results of a consensus process by an International
Working Group. Haematologica. (2007) 92:95–100. doi: 10.3324/haemato
l.10699
6. Oran B, Donato M, Aleman A, Hosing C, Korbling M, Detry MA,
et al. Transplant-associated microangiopathy in patients receiving
tacrolimus following allogeneic stem cell transplantation: risk factors
and response to treatment. Biol Blood Marrow Transplant. (2007) 13:469–77.
doi: 10.1016/j.bbmt.2006.11.020
7. Cho BS, Min CK, Eom KS, Kim YJ, Kim HJ, Lee S, et al. Clinical impact of
thrombotic microangiopathy on the outcome of patients with acute graft-
versus-host disease after allogeneic hematopoietic stem cell transplantation.
Bone Marrow Transplant. (2008) 41:813. doi: 10.1038/sj.bmt.1705976
8. Peyvandi F, Siboni SM, Lambertenghi Deliliers D, Lavoretano S, De
Fazio N, Moroni B, et al. Prospective study on the behaviour of
the metalloprotease ADAMTS13 and of von Willebrand factor after
bone marrow transplantation. Br J Haematol. (2006) 134:187–95.
doi: 10.1111/j.1365-2141.2006.06126.x
9. Gavriilaki E, Yuan X, Ye Z, Ambinder AJ, Shanbhag SP, Streiff MB, et al.
Modified Ham test for atypical hemolytic uremic syndrome. Blood. (2015)
125:3637–46. doi: 10.1182/blood-2015-02-629683
10. Erdbruegger U, Woywodt A, Kirsch T, Haller H, Haubitz M. Circulating
endothelial cells as a prognostic marker in thrombotic microangiopathy. Am
J Kidney Dis. (2006) 48:564–70. doi: 10.1053/j.ajkd.2006.06.013
11. Pihusch V, Rank A, Steber R, PihuschM, Pihusch R, Toth B, et al. Endothelial
cell–derived microparticles in allogeneic hematopoietic stem cell recipients.
Transplantation. (2006) 81:1405–9. doi: 10.1097/01.tp.0000209218.2
4916.ba
12. Gloude NJ, Khandelwal P, Luebbering N, Lounder DT, Jodele S, Alder MN,
et al. Circulating dsDNA, endothelial injury, and complement activation
in thrombotic microangiopathy and GVHD. Blood. (2017) 130:1259–66.
doi: 10.1182/blood-2017-05-782870
13. Béland S, Vallin P, Désy O, Lévesque E, De Serres SA. Effects of
alloantibodies to human leukocyte antigen on endothelial expression and
serum levels of thrombomodulin. J Thromb Haemost. (2017) 15:1020–31.
doi: 10.1111/jth.13661
14. Laskin BL, Maisel J, Goebel J, Yin HJ, Luo G, Khoury JC, et al. Renal
arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell
transplantation–associated thrombotic microangiopathy. Transplantation.
(2013) 96:217–23. doi: 10.1097/TP.0b013e31829807aa
15. Warren M, Jodele S, Dandoy CE, Myers KC, Wallace G, Nelson A,
et al. A complete histologic approach to gastrointestinal biopsy from
hematopoietic stem cell transplant patients with evidence of transplant-
associated gastrointestinal thrombotic microangiopathy. Arch Pathol Lab
Med. (2017) 141:1558–66. doi: 10.5858/arpa.2016-0599-RA
16. Uderzo C, Bonanomi S, Busca A, Renoldi M, Ferrari P, Iacobelli M, et al. Risk
factors and severe outcome in thrombotic microangiopathy after allogeneic
hematopoietic stem cell transplantation. Transplantation. (2006) 82:638–44.
doi: 10.1097/01.tp.0000230373.82376.46
17. Daly AS, Hasegawa WS, Lipton JH, Messner HA, Kiss TL.
Transplantation-associated thrombotic microangiopathy is associated
with transplantation from unrelated donors, acute graft-versus-host disease
and venoocclusive disease of the liver. Transfus Apher Sci. (2002) 27:3–12.
doi: 10.1016/S1473-0502(02)00020-4
18. Jodele S, Dandoy CE, Myers K, Wallace G, Lane A, Teusink-Cross A, et al.
High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic
microangiopathy and organ injury after autologous stem cell transplantation
in patients with neuroblastoma. Bone Marrow Transplant. (2018) 53:1311–8.
doi: 10.1038/s41409-018-0159-8
19. Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble
in the kidneys and beyond: hematopoietic stem cell transplantation–
associated thrombotic microangiopathy. Blood. (2011) 118:1452–62.
doi: 10.1182/blood-2011-02-321315
20. Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al.
Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-
occlusive disease in pediatric patients: a new classification from the European
society for blood and marrow transplantation. Bone Marrow Transplant.
(2017) 53:138. doi: 10.1038/bmt.2017.161
21. Tatekawa S, Kohno A, Ozeki K, Watamoto K, Ueda N, Yamaguchi Y,
et al. A novel diagnostic and prognostic biomarker panel for endothelial
cell damage–related complications in allogeneic transplantation. Biol Blood
Marrow Transplant. (2016) 22:1573–81. doi: 10.1016/j.bbmt.2016.05.018
22. Seeber C, Hiller E, Holler E, Kolb H. Increased levels of tissue plasminogen
activator (t-PA) and tissue plasminogen activator inhibitor (PAI) correlate
with tumor necrosis factor alpha (TNF alpha)-release in patients suffering
from microangiopathy following allogeneic bone marrow transplantation
(BMT). Thromb Res. (1992) 66:373–83. doi: 10.1016/0049-3848(92)90286-J
23. Laskin BL, Nehus E, Goebel J, Furth S, Davies SM, Jodele S. Estimated
versus measured glomerular filtration rate in children before hematopoietic
cell transplantation. Biol Blood Marrow Transplant. (2014) 20:2056–61.
doi: 10.1016/j.bbmt.2014.07.008
24. Wirtschafter E, VanBeek C, Linhares Y. Bone marrow transplant-associated
thrombotic microangiopathy without peripheral blood schistocytes: a case
report and review of the literature. Exp Hematol Oncol. (2018) 7:14.
doi: 10.1186/s40164-018-0106-9
25. El-Bietar J, Warren M, Dandoy C, Myers KC, Lane A, Wallace
G, et al. Histologic features of intestinal thrombotic microangiopathy
in pediatric and young adult patients after hematopoietic stem cell
transplantation. Biol Blood Marrow Transplant. (2015) 21:1994–2001.
doi: 10.1016/j.bbmt.2015.06.016
26. Cox K, Punn R, Weiskopf E, Pinsky BA, Kharbanda S. Pericardial effusion
following hematopoietic cell transplantation in children and young adults is
Frontiers in Pediatrics | www.frontiersin.org 12 April 2019 | Volume 7 | Article 133
Dvorak et al. TA-TMA in Pediatric HCT
associated with increased risk of mortality. Biol Blood Marrow Transplant.
(2017) 23:1165–9. doi: 10.1016/j.bbmt.2017.03.028
27. Dandoy CE, Davies SM, Hirsch R, Chima RS, Paff Z, CashM, et al. Abnormal
echocardiography 7 days after stem cell transplantation may be an early
indicator of thrombotic microangiopathy. Biol Blood Marrow Transplant.
(2015) 21:113–8. doi: 10.1016/j.bbmt.2014.09.028
28. Jodele S, Hirsch R, Laskin B, Davies S, Witte D, Chima R. Pulmonary arterial
hypertension in pediatric patients with hematopoietic stem cell transplant–
associated thrombotic microangiopathy. Biol Blood Marrow Transplant.
(2013) 19:202–7. doi: 10.1016/j.bbmt.2012.08.022
29. Cataland SR, Holers VM, Geyer S, Yang S, Wu HM. Biomarkers
of terminal complement activation confirm the diagnosis of aHUS
and differentiate aHUS from TTP. Blood. (2014) 123:3733–8.
doi: 10.1182/blood-2013-12-547067
30. Abusin GA, Abu-Arja R, Bajwa RPS, Horwitz EM, Auletta JJ, Rangarajan
HG. Severe transplant-associated thrombotic microangiopathy in patients
with hemoglobinopathies. Pediatr Blood Cancer. (2017) 64:e26503.
doi: 10.1002/pbc.26503
31. Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, et al.
Abnormalities in the alternative pathway of complement in children with
hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Blood. (2013) 122:2003–7. doi: 10.1182/blood-2013-05-501445
32. Grube M, Wolff D, Ahrens N, Herzberg PY, Herr W, Holler E. ABO
blood group antigen mismatch has an impact on outcome after allogeneic
peripheral blood stem cell transplantation. Clin Transplant. (2016) 30:1457–
65. doi: 10.1111/ctr.12840
33. Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-
Bacchi V, Goodship THJ, et al. Atypical aHUS: state of the art.Mol Immunol.
(2015) 67:31–42. doi: 10.1016/j.molimm.2015.03.246
34. Jodele S, Zhang K, Zou F, Laskin B, Dandoy CE, Myers KC,
et al. The genetic fingerprint of susceptibility for transplant-
associated thrombotic microangiopathy. Blood. (2016) 127:989–96.
doi: 10.1182/blood-2015-08-663435
35. Ardissino G, Salardi S, Berra S, Colussi G, Cugno M, Zecca M, et al.
Acquired complement regulatory gene mutations and hematopoietic stem
cell transplant–related thrombotic microangiopathy. Biol Blood Marrow
Transplant. (2017) 23:1580–2. doi: 10.1016/j.bbmt.2017.05.013
36. Rachakonda SP, Dai H, Penack O, Blau O, Blau IW, Radujkovic A,
et al. Single nucleotide polymorphisms in CD40L predict endothelial
complications and mortality after allogeneic stem-cell transplantation. J Clin
Oncol. (2018) 36:789–800. doi: 10.1200/JCO.2017.76.4662
37. Balassa K, Andrikovics H, Remenyi P, Batai A, Bors A, Kiss KP,
et al. The potential role of HLA-DRB1∗11 in the development
and outcome of haematopoietic stem cell transplantation-associated
thrombotic microangiopathy. Bone Marrow Transplant. (2015) 50:1321.
doi: 10.1038/bmt.2015.161
38. Zeisbrich M, Becker N, Benner A, Radujkovic A, Schmitt K, Beimler J,
et al. Transplant-associated thrombotic microangiopathy is an endothelial
complication associated with refractoriness of acute GvHD. Bone Marrow
Transplant. (2017) 52:1399. doi: 10.1038/bmt.2017.119
39. Postalcioglu M, Kim HT, Obut F, Yilmam OA, Yang J, Byun BC, et al.
Impact of thrombotic microangiopathy on renal outcomes and survival
after hematopoietic stem cell transplantation. Biol BloodMarrow Transplant.
(2018) 24:2344–53. doi: 10.1016/j.bbmt.2018.05.010
40. NakamaeH, Yamane T, Hasegawa T, NakamaeM, Terada Y, Hagihara K, et al.
Risk factor analysis for thrombotic microangiopathy after reduced-intensity
or myeloablative allogeneic hematopoietic stem cell transplantation. Am J
Hematol. (2006) 81:525–31. doi: 10.1002/ajh.20648
41. Willems E, Baron F, Seidel L, Frère P, Fillet G, Beguin Y. Comparison
of thrombotic microangiopathy after allogeneic hematopoietic cell
transplantation with high-dose or nonmyeloablative conditioning. Bone
Marrow Transplant. (2009) 45:689. doi: 10.1038/bmt.2009.230
42. Logan AC, Wang Z, Alimoghaddam K, Wong RM, Lai T, Negrin RS,
et al. ABO mismatch is associated with increased nonrelapse mortality after
allogeneic hematopoietic cell transplantation. Biol BloodMarrow Transplant.
(2015) 21:746–54. doi: 10.1016/j.bbmt.2014.12.036
43. Worel N, Kalhs P, Keil F, Prinz E, Moser K, Schulenburg A, et al. ABO
mismatch increases transplant-related morbidity and mortality in patients
given nonmyeloablative allogeneic HPC transplantation. Transfusion. (2003)
43:1153–61. doi: 10.1046/j.1537-2995.2003.00465.x
44. Worel N, Greinix HT, Leitner G, Mitterbauer M, Rabitsch W, Rosenmayr A,
et al. ABO-incompatible allogeneic hematopoietic stem cell transplantation
following reduced-intensity conditioning: close association with transplant-
associated microangiopathy. Transfus Apher Sci. (2007) 36:297–304.
doi: 10.1016/j.transci.2007.03.004
45. Lapierre V, Mahé C, Aupérin A, Stambouli F, Oubouzar N,
Tramalloni D, et al. Platelet transfusion containing ABO-incompatible
plasma and hepatic veno-occlusive disease after hematopoietic
transplantation in young children. Transplantation. (2005) 80:314–9.
doi: 10.1097/01.tp.0000167758.63247.f4
46. Shayani S, Palmer J, Stiller T, Liu X, Thomas SH, Khuu T, et al.
Thrombotic microangiopathy associated with sirolimus level after allogeneic
hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-
versus-host disease prophylaxis. Biol Blood Marrow Transplant. (2013)
19:298–304. doi: 10.1016/j.bbmt.2012.10.006
47. Glezerman I, Jhaveri K, Watson T, Edwards A, Papadopoulos E,
Young J, et al. Chronic kidney disease, thrombotic microangiopathy,
and hypertension following T cell-depleted hematopoietic stem cell
transplantation. Biol Blood Marrow Transplant. (2010) 16:976–84.
doi: 10.1016/j.bbmt.2010.02.006
48. Kaloyannidis P, Mallouri D, Hatziioannou K, Batsis I, Yannaki E,
Papavasileiou P, et al. Low body mass index is an independent risk factor
for transplant-associated microangiopathy following total-body irradiation-
based conditioning regimens. Biol Blood Marrow Transplant. (2008)
14:1076–8. doi: 10.1016/j.bbmt.2008.05.022
49. Shimoni A, Yeshurun M, Hardan I, Avigdor A, Ben-Bassat I,
Nagler A. Thrombotic microangiopathy after allogeneic stem cell
transplantation in the era of reduced-intensity conditioning: the
incidence is not reduced. Biol Blood Marrow Transplant. (2004) 10:484–93.
doi: 10.1016/j.bbmt.2004.03.002
50. Eissner G, Multhoff G, Gerbitz A, Kirchner S, Bauer S, Haffner S,
et al. Fludarabine induces apoptosis, activation, and allogenicity in human
endothelial and epithelial cells: protective effect of defibrotide. Blood. (2002)
100:334–40. doi: 10.1182/blood.V100.1.334
51. Long-Boyle J, Green K, Brunstein C, Cao Q, Rogosheske J,
Weisdorf D, et al. High fludarabine exposure and relationship with
treatment-related mortality after nonmyeloablative hematopoietic cell
transplantation. Bone Marrow Transplant. (2011) 46:20–6. doi: 10.1038/
bmt.2010.53
52. Ivaturi V, Dvorak CC, Chan D, Liu T, Cowan MJ, Wahlstrom
J, et al. Pharmacokinetics and model-based dosing to optimize
fludarabine therapy in pediatric hematopoietic cell transplant recipients.
Biol Blood Marrow Transplant. (2017) 23:1701–13. doi: 10.1016/
j.bbmt.2017.06.021
53. Schechter T, Perez-Albuerne E, Lin TF, Irwin MS, Essa M,
Desai AV, et al. Veno-occlusive disease after high-dose busulfan–
melphalan in neuroblastoma. Bone Marrow Transplant. (2018).
doi: 10.1038/s41409-018-0298-y. [Epub ahead of print].
54. Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E, et al. Sirolimus
and thrombotic microangiopathy after allogeneic hematopoietic stem
cell transplantation. Biol Blood Marrow Transplant. (2005) 11:551–7.
doi: 10.1016/j.bbmt.2005.04.007
55. Carmona A, Díaz-Ricart M, Palomo M, Molina P, Pino M, Rovira
M, et al. Distinct deleterious effects of cyclosporine and tacrolimus
and combined tacrolimus–sirolimus on endothelial cells: protective
effect of defibrotide. Biol Blood Marrow Transplant. (2013) 19:1439–45.
doi: 10.1016/j.bbmt.2013.07.001
56. Kraft S, Bollinger N, Bodenmann B, Heim D, Bucher C, Lengerke C, et al.
High mortality in hematopoietic stem cell transplant-associated thrombotic
microangiopathy with and without concomitant acute graft-versus-host
disease. Bone Marrow Transplant. (2018). doi: 10.1038/s41409-018-0293-3.
[Epub ahead of print].
57. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, et al.
ST2 as a marker for risk of therapy-resistant graft-versus-host disease
and death. N Engl J Med. (2013) 369:529–39. doi: 10.1056/NEJMoa12
13299
Frontiers in Pediatrics | www.frontiersin.org 13 April 2019 | Volume 7 | Article 133
Dvorak et al. TA-TMA in Pediatric HCT
58. Rotz SJ, Dandoy CE, Davies SM. ST2 and Endothelial injury as a link
between GVHD and microangiopathy. N Engl J Med. (2017) 376:1189–90.
doi: 10.1056/NEJMc1700185
59. Tichelli A, Gratwohl A. Vascular endothelium as ‘novel’ target of graft-
versus-host disease. Best Pract Res Clin Haematol. (2008) 21:139–48.
doi: 10.1016/j.beha.2008.02.002
60. Dietrich S, Falk CS, Benner A, Karamustafa S, Hahn E, Andrulis M, et al.
Endothelial vulnerability and endothelial damage are associated with risk
of graft-versus-host disease and response to steroid treatment. Biol Blood
Marrow Transplant. (2013) 19:22–7. doi: 10.1016/j.bbmt.2012.09.018
61. Luft T, Dietrich S, Falk C, Conzelmann M, Hess M, Benner A, et al. Steroid-
refractory GVHD: T-cell attack within a vulnerable endothelial system.
Blood. (2011) 118:1685–92. doi: 10.1182/blood-2011-02-334821
62. Dandoy CE, Haslam D, Lane A, Jodele S, Demmel K, El-Bietar
J, et al. Healthcare burden, risk factors, and outcomes of mucosal
barrier injury laboratory-confirmed bloodstream infections after stem
cell transplantation. Biol Blood Marrow Transplant. (2016) 22:1671–7.
doi: 10.1016/j.bbmt.2016.06.002
63. Arai Y, Yamashita K, Mizugishi K, Watanabe T, Sakamoto S,
Kitano T, et al. Serum neutrophil extracellular trap levels predict
thrombotic microangiopathy after allogeneic stem cell transplantation.
Biol Blood Marrow Transplant. (2013) 19:1683–9. doi: 10.1016/
j.bbmt.2013.09.005
64. McDonald B, Davis RP, Kim S-J, Tse M, Esmon CT, Kolaczkowska E,
et al. Platelets and neutrophil extracellular traps collaborate to promote
intravascular coagulation during sepsis in mice. Blood. (2017) 129:1357–67.
doi: 10.1182/blood-2016-09-741298
65. Schoergenhofer C, Schwameis M, Wohlfarth P, Brostjan C, Abrams ST, Toh
C-H, et al. Granulocyte colony-stimulating factor (G-CSF) increases histone-
complexed DNA plasma levels in healthy volunteers. Clin Exp Med. (2017)
17:243–9. doi: 10.1007/s10238-016-0413-6
66. Takatsuka H, Wakae T, Mori A, Okada M, Fujimori Y, Takemoto Y, et al.
Endothelial damage caused by cytomegalovirus and human herpesvirus-6.
Bone Marrow Transplant. (2003) 31:475. doi: 10.1038/sj.bmt.1703879
67. Haines HL, Laskin BL, Goebel J, Davies SM, Yin HJ, Lawrence J,
et al. Blood, and not urine, BK viral load predicts renal outcome
in children with hemorrhagic cystitis following hematopoietic stem
cell transplantation. Biol Blood Marrow Transplant. (2011) 17:1512–9.
doi: 10.1016/j.bbmt.2011.02.012
68. Myers GD, Krance RA, Weiss H, Kuehnle I, Demmler G, Heslop HE,
et al. Adenovirus infection rates in pediatric recipients of alternate donor
allogeneic bone marrow transplants receiving either antithymocyte globulin
(ATG) or alemtuzumab (Campath). Bone Marrow Transplant. (2005)
36:1001. doi: 10.1038/sj.bmt.1705164
69. Khosla J, Yeh AC, Spitzer TR, Dey BR. Hematopoietic stem cell
transplant-associated thrombotic microangiopathy: current paradigm
and novel therapies. Bone Marrow Transplant. (2017) 53:129.
doi: 10.1038/bmt.2017.207
70. Koh KK, Bui MN, Hathaway L, Csako G, Waclawiw MA, Panza JA,
et al. Mechanism by which quinapril improves vascular function
in coronary artery disease. Am J Cardiol. (1999) 83:327–31.
doi: 10.1016/S0002-9149(98)00862-5
71. Yang S, McGookey M, Wang Y, Cataland SR, Wu HM. Effect of
blood sampling, processing, and storage on the measurement of
complement activation biomarkers. Am J Clin Pathol. (2015) 143:558–65.
doi: 10.1309/AJCPXPD7ZQXNTIAL
72. Chen J, Losos M, Yang S, Li J, Wu H, Cataland S. Increased
complement activation during platelet storage. Transfusion. (2017) 57:2182–
8. doi: 10.1111/trf.14215
73. Hale GA, Bowman LC, Rochester RJ, Benaim E, Heslop HE, Krance RA, et al.
Hemolytic uremic syndrome after bone marrow transplantation: clinical
characteristics and outcome in children. Biol Blood Marrow Transplant.
(2005) 11:912–20. doi: 10.1016/j.bbmt.2005.07.012
74. Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human
soluble tumor necrosis factor receptor fusion protein as treatment for steroid
refractory graft-versus-host disease following allogeneic hematopoietic stem
cell transplantation. Am J Hematol. (2007) 82:45–52. doi: 10.1002/ajh.20752
75. Antin J, Weinstein H, Guinan E, McCarthy P, Bierer B, Gilliland D, et al.
Recombinant human interleukin-1 receptor antagonist in the treatment of
steroid-resistant graft-versus-host disease. Blood. (1994) 84:1342–8.
76. Grimaldi F, Potter V, Perez-Abellan P, Veluchamy JP, Atif M, Grain R,
et al. Mixed T cell chimerism after allogeneic hematopoietic stem cell
transplantation for severe aplastic anemia using an alemtuzumab-containing
regimen is shaped by persistence of recipient CD8T cells. Biol Blood Marrow
Transplant. (2017) 23:293–9. doi: 10.1016/j.bbmt.2016.11.003
77. McCann S, Passweg J, Bacigalupo A, Locasciulli A, Locatelli F, Ryan J, et al.
The influence of cyclosporin alone, or cyclosporin and methotrexate, on the
incidence of mixed haematopoietic chimaerism following allogeneic sibling
bone marrow transplantation for severe aplastic anaemia. Bone Marrow
Transplant. (2006) 39:109. doi: 10.1038/sj.bmt.1705552
78. Wolff D, Wilhelm S, Hahn J, Gentilini C, Hilgendorf I, Steiner B, et al.
Replacement of calcineurin inhibitors with daclizumab in patients with
transplantation-associated microangiopathy or renal insufficiency associated
with graft-versus-host disease. Bone Marrow Transplant. (2006) 38:445.
doi: 10.1038/sj.bmt.1705454
79. Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, et al.
Variable eculizumab clearance requires pharmacodynamic monitoring to
optimize therapy for thrombotic microangiopathy after hematopoietic stem
cell transplantation. Biol Blood Marrow Transplant. (2016) 22:307–15.
doi: 10.1016/j.bbmt.2015.10.002
80. Jodele S, Laskin BL, Goebel J, Khoury JC, Pinkard SL, Carey PM, et al. Does
early initiation of therapeutic plasma exchange improve outcome in pediatric
stem cell transplant–associated thrombotic microangiopathy? Transfusion.
(2013) 53:661–7. doi: 10.1111/j.1537-2995.2012.03776.x
81. Choi CM, Schmaier AH, Snell MR, Lazarus H. Thrombotic microangiopathy
in haematopoietic stem cell transplantation. Drugs. (2009) 69:183–9.
doi: 10.2165/00003495-200969020-00004
82. Lovric S, Lukasz A, Hafer C, Kielstein JT, Haubitz M, Haller H, et al.
Removal of elevated circulating angiopoietin-2 by plasma exchange – a
pilot study in critically ill patients with thrombotic microangiopathy and
anti-glomerular basement membrane disease. Thromb Haemost. (2010)
104:1038–43. doi: 10.1160/TH10-02-0138
83. Bohl SR, Kuchenbauer F, von Harsdorf S, Kloevekorn N, Schönsteiner
SS, Rouhi A, et al. Thrombotic microangiopathy after allogeneic
stem cell transplantation: a comparison of eculizumab therapy and
conventional therapy. Biol Blood Marrow Transplant. (2017) 23:2172–7.
doi: 10.1016/j.bbmt.2017.08.019
84. Jodele S, Dandoy CE, Danziger-Isakov L, Myers KC, El-Bietar J, Nelson
A, et al. Terminal complement blockade after hematopoietic stem cell
transplantation is safe without meningococcal vaccination. Biol Blood
Marrow Transplant. (2016) 22:1337–40. doi: 10.1016/j.bbmt.2016.03.032
85. Jodele S. Complement in pathophysiology and treatment of transplant-
associated thrombotic microangiopathies. Semin Hematol. (2018) 55:159–66.
doi: 10.1053/j.seminhematol.2018.04.003
86. Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S,
Füreder W, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients
with PNH naive to complement inhibitors: the 301 study. Blood. (2018)
133:530–9. doi: 10.1182/blood-2018-09-876136
87. Harder MJ, Kuhn N, Schrezenmeier H, Höchsmann B, von Zabern I,
Weinstock C, et al. Incomplete inhibition by eculizumab: mechanistic
evidence for residual C5 activity during strong complement activation.
Blood. (2017) 129:970–80. doi: 10.1182/blood-2016-08-732800
88. Goodship THJ, Pinto F, Weston-Davies WH, Silva J, Nishimura
J-i, Nunn MA, et al. Use of the complement inhibitor Coversin
to treat HSCT-associated TMA. Blood Adv. (2017) 1:1254–8.
doi: 10.1182/bloodadvances.2016002832
89. Fujiwara H, Maeda Y, Sando Y, Nakamura M, Tani K, Ishikawa T,
et al. Treatment of thrombotic microangiopathy after hematopoietic stem
cell transplantation with recombinant human soluble thrombomodulin.
Transfusion. (2016) 56:886–92. doi: 10.1111/trf.13437
90. Corti P, Uderzo C, Tagliabue A, Della Volpe A, Annaloro C, Tagliaferri E,
et al. Defibrotide as a promising treatment for thrombotic thrombocytopenic
purpura in patients undergoing bone marrow transplantation. Bone Marrow
Transplant. (2002) 29:542. doi: 10.1038/sj.bmt.1703414
Frontiers in Pediatrics | www.frontiersin.org 14 April 2019 | Volume 7 | Article 133
Dvorak et al. TA-TMA in Pediatric HCT
91. Martínez-Muñoz ME, Forés R, Lario A, Bautista G, Bueno JL, de Miguel
C, et al. Use of defibrotide to treat adult patients with transplant-associated
thrombotic microangiopathy. Bone Marrow Transplant. (2019) 54:142–5.
doi: 10.1038/s41409-018-0256-8
92. Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B,
Rovelli A, et al. Defibrotide for prophylaxis of hepatic veno-occlusive
disease in paediatric haemopoietic stem-cell transplantation: an open-
label, phase 3, randomised controlled trial. Lancet. (2012) 379:1301–9.
doi: 10.1016/S0140-6736(11)61938-7
93. HanssonMEA, Norlin A-C, Omazic B,WikströmA-C, Bergman P,Winiarski
J, et al. Vitamin D levels affect outcome in pediatric hematopoietic stem
cell transplantation. Biol Blood Marrow Transplant. (2014) 20:1537–43.
doi: 10.1016/j.bbmt.2014.05.030
94. Wallace G, Jodele S, Howell J, Myers KC, Teusink A, Zhao X, et al.
Vitamin D deficiency and survival in children after hematopoietic
stem cell transplant. Biol Blood Marrow Transplant. (2015) 21:1627–31.
doi: 10.1016/j.bbmt.2015.06.009
95. Marampon F, Gravina GL, Festuccia C, Popov VM, Colapietro
EA, Sanità P, et al. Vitamin D protects endothelial cells from
irradiation-induced senescence and apoptosis by modulating
MAPK/SirT1 axis. J Endocrinol Invest. (2016) 39:411–22. doi: 10.1007/
s40618-015-0381-9
96. Takatsuka H, Takemoto Y, Iwata N, Suehiro A, Hamano T, Okamoto
T, et al. Oral eicosapentaenoic acid for complications of bone
marrow transplantation. Bone Marrow Transplant. (2001) 28:769.
doi: 10.1038/sj.bmt.1703226
97. Bartelink IH, Lalmohamed A, van Reij EML, Dvorak CC, Savic RM,
Zwaveling J, et al. Association of busulfan exposure with survival and toxicity
after haemopoietic cell transplantation in children and young adults: a
multicentre, retrospective cohort analysis. Lancet Haematol. (2016) 3:e526-
36. doi: 10.1016/S2352-3026(16)30114-4
98. McCune J, Batchelder A, Guthrie K, Witherspoon R, Appelbaum F, Phillips
B, et al. Personalized dosing of cyclophosphamide in the total body
irradiation–cyclophosphamide conditioning regimen: a phase II trial in
patients with hematologic malignancy. Clin Pharmacol Ther. (2009) 85:615–
22. doi: 10.1038/clpt.2009.27
99. Arai Y, Nishinaka Y, Arai T, Morita M, Mizugishi K, Adachi S, et al.
Uric acid induces NADPH oxidase-independent neutrophil extracellular
trap formation. Biochem Biophys Res Commun. (2014) 443:556–61.
doi: 10.1016/j.bbrc.2013.12.007
100. Yeh AC, Brunner AM, Spitzer TR, Chen Y-B, Coughlin E, McAfee S,
et al. Phase I study of urate oxidase in the reduction of acute graft-versus-
host disease after myeloablative allogeneic stem cell transplantation.
Biol Blood Marrow Transplant. (2014) 20:730–4. doi: 10.1016/
j.bbmt.2014.02.003
101. Shi M-M, Kong Y, Song Y, Sun Y-Q, Wang Y, Zhang X-H, et al.
Atorvastatin enhances endothelial cell function in posttransplant
poor graft function. Blood. (2016) 128:2988–99. doi: 10.1182/
blood-2016-03-702803
102. Gomez SA, Abrey-Recalde MJ, Panek CA, Ferrarotti NF, Repetto MG,Mejías
MP, et al. The oxidative stress induced in vivo by Shiga toxin-2 contributes
to the pathogenicity of haemolytic uraemic syndrome. Clin Exp Immunol.
(2013) 173:463–72. doi: 10.1111/cei.12124
103. Rottenstreich A, Hochberg-Klein S, Rund D, Kalish Y. The role of
N-acetylcysteine in the treatment of thrombotic thrombocytopenic
purpura. J Thromb Thrombolysis. (2016) 41:678–83. doi: 10.1007/
s11239-015-1259-6
104. Tamari R, Chung SS, Papadopoulos EB, Jakubowski AA, Hilden P,
Devlin SM, et al. CD34-selected hematopoietic stem cell transplants
conditioned with myeloablative regimens and antithymocyte globulin
for advanced myelodysplastic syndrome: limited graft-versus-host disease
without increased relapse. Biol BloodMarrow Transplant. (2015) 21:2106–14.
doi: 10.1016/j.bbmt.2015.07.010
105. Jacoby E, Chen A, Loeb DM, Gamper CJ, Zambidis E, Llosa NJ, et al.
Single-agent post-transplantation cyclophosphamide as graft-versus-host
disease prophylaxis after human leukocyte antigen–matched related bone
marrow transplantation for pediatric and young adult patients with
hematologic malignancies. Biol Blood Marrow Transplant. (2016) 22:112–8.
doi: 10.1016/j.bbmt.2015.08.034
106. Koura DT, Horan JT, Langston AA, Qayed M, Mehta A, Khoury HJ, et al. In
vivo T cell costimulation blockade with abatacept for acute graft-versus-host
disease prevention: a first-in-disease trial. Biol Blood Marrow Transplant.
(2013) 19:1638–49. doi: 10.1016/j.bbmt.2013.09.003
107. Alexander S, Fisher BT, Gaur AH, Dvorak CC, Villa Luna D,
Dang H, et al. Effect of levofloxacin prophylaxis on bacteremia in
children with acute leukemia or undergoing hematopoietic stem cell
transplantation: a randomized clinical trial. JAMA. (2018) 320:995–1004.
doi: 10.1001/jama.2018.12512
108. Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima
M, et al. Allogeneic hematopoietic stem cell transplantation after
rituximab-containing myeloablative preparative regimen for acute
lymphoblastic leukemia. Bone Marrow Transplant. (2006) 38:203.
doi: 10.1038/sj.bmt.1705425
109. Cutler C, Kim HT, Bindra B, Sarantopoulos S, Ho VT, Chen Y-B,
et al. Rituximab prophylaxis prevents corticosteroid-requiring chronic
GVHD after allogeneic peripheral blood stem cell transplantation:
results of a phase 2 trial. Blood. (2013) 122:1510–7. doi: 10.1182/
blood-2013-04-495895
110. Horváth O, Kállay K, Csuka D, Mezo B, Sinkovits G, Kassa C, et al.
Early increase in complement terminal pathway activation marker sC5b-
9 is predictive for the development of thrombotic microangiopathy after
stem cell transplantation. Biol Blood Marrow Transplant. (2018) 24:989–96.
doi: 10.1016/j.bbmt.2018.01.009
111. Kanamori H, Maruta A, Sasaki S, Yamazaki E, Ueda S, Katoh K, et al.
Diagnostic value of hemostatic parameters in bone marrow transplant-
associated thrombotic microangiopathy. Bone Marrow Transplant. (1998)
21:705. doi: 10.1038/sj.bmt.1701151
112. Zeigler ZR, Kelton JG, Moore JC, Shadduck RK, Iii D, Nath R,
et al. Calpain activity in bone marrow transplant-associated thrombotic
thrombocytopenic purpura. Bone Marrow Transplant. (1999) 24:641.
doi: 10.1038/sj.bmt.1701928
113. Schuh M, Bennett M, Lane A, Jodele S, Laskin B, Devarajan P. Haptoglobin
degradation product as a novel serum biomarker for hematopoietic stem cell
transplant-associated thrombotic microangiopathy. Pediatr Nephrol. (2019)
34:865–71. doi: 10.1007/s00467-018-4178-x
Conflict of Interest Statement: CD has received consulting fees from Alexion,
Inc. (manufacturers of eculizumab) and Jazz Pharmaceuticals (manufacturers of
defibrotide). CH receives research funding from Jazz Pharmaceuticals. KS has
received research funding from Alexion, Inc.
The authors declare that the research was conducted in the absence of any
commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2019 Dvorak, Higham and Shimano. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pediatrics | www.frontiersin.org 15 April 2019 | Volume 7 | Article 133
